Rajiv Dhir, MBBS, MBA
Professor of Pathology


Dr. Dhir is Chief of Pathology at UPMC Shadyside, Director of International Business Development, Director of the Genitourinary Pathology Center of Excellence, Director of the Paraffin Tissue Array Facility, and Director of the Health Science Tissue Bank.

Office Location:
Room WG 02.6
UPMC Shadyside Hospital
Contact Information:
Office Phone: 412-623-1321
Beeper: 412-765-8600
E-Mail: dhirr@upmc.edu

Education

  • MBBS - New Delhi, India, 1983
  • MBA - University of Pittsburgh, 2012

Clinical Expertise

Dr. Dhir is a practicing pathologist and currently serves as the Chief of Pathology at Shadyside Hospital, one of the flagship hospitals of the University of Pittsburgh. He is a board certified pathologist with subspecialty fellowship training in Genitourinary pathology. He has served as the director of the GU center of excellence at the University of Pittsburgh for the past nine years.

Dr. Dhir's interests include the molecular changes in bladder, renal and prostate carcinogenesis. The Pittsburgh GU group has an ongoing research study evaluated RNA expression, SNP, micro-RNA and proteomic perturbations to get a global integrated view of disease onset and progression. Current research focuses on translation of some of the discoveries into validated, clinically relevant tests. There is also ongoing work on correlative work aimed at sub-cellular changes and their correlation with response to different treatment modalities and assessment of chemo-preventive approaches.

He has been involved in numerous clinical, basic and translational projects focused on GU diseases and has been a recipient of NIH/NCI grants in this area. His major focus of interest is the identification and validation of novel targets for diagnostic, prognostic and therapeutic use.

He has been the Medical Director of the Health Sciences Tissue Bank of the University of Pittsburgh since 1997. He oversees the tissue and biological specimen collection at the 3 flagship hospitals of the University of Pittsburgh Health Systems. This Tissue Resource has developed into a large resource for basic and translational research at the University of Pittsburgh as well collaborative research with investigators outside the University of Pittsburgh. This facility is a designated core facility for the University of Pittsburgh and the University of Pittsburgh Cancer Institute.

Dr. Dhir is the Principal Investigator for the Tissue Source Sites grant (part of The Cancer Genome Atlas initiative). The University of Pittsburgh has been one the largest contributors to the TCGA effort having provided over 1000 cases spanning a variety of tumor types.

The Tissue Banking initiatives have received extensive funding from various initiatives including the Cancer Genome Atlas Project, caHUB, Lung, Melanoma and Head & Neck SPORES, the Gynecologic Disease Program, the Cooperative Prostate Cancer Tissue Resource, the Shared Pathology Informatics Network, the Early Disease Research Network and others.

Dr. Dhir has been one of the key physicians involved in developing and implementing an Institutional Honest Broker system, incorporating the key data aggregation agencies at the University of Pittsburgh. He is also involved in the Informatics related initiatives in the Tissue Banking space. He was the co-PI on the CaTissue Core adopter grant from the CaBIG. He has also played an important role in the development of organ specific databases and associated tools at the University of Pittsburgh.

He has published 10 book chapters, has over 125 peer reviewed publications and has over 75 published abstracts.

He was also one of the participants in the RAND report on Tissue Banking. He has also been an invited member of the Marble Arch group, an international consortium of Tissue Bankers.

Research Expertise

  1. GU Pathology and Clinical and translational aspects of genitourinary neoplasms
  2. Biomarkers related to Genitourinary disease; with special interest in GU neoplasms
  3. Human tissue banking

Recent Publications

View Dr. Dhir's publications on PubMed

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study. Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC. Gynecol Oncol. 2012 Jan 16.

Altered CXCR3 Isoform Expression Regulates Prostate Cancer Cell Migration and Invasion. Wu Q, Dhir R, Wells A. Mol Cancer. 2012 Jan 11; 11(1):3.

Relative quantitation of proteins in expressed prostatic secretion with a stable isotope labeled secretome standard. Zhao T, Zeng X, Bateman NW, Sun M, Teng PN, Bigbee WL, Dhir R, Nelson JB, Conrads TP, Hood BL. J Proteome Res. 2012 Feb 3;11(2):1089-99.

Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, Holt RJ, Proutski V, Ahdesmaki M, Farztdinov V, Goffard N, Hey P, McDyer F, Mulligan K, Mussen J, O'Brien E, Oliver G, Walker SM, Mulligan JM, Wilson C, Winter A, O'Donoghue D, Mulcahy H, O'Sullivan J, Sheahan K, Hyland J, Dhir R, Bathe OF, Winqvist O, Manne U, Shanmugam C, Ramaswamy S, Leon EJ, Smith WI Jr, McDermott U, Wilson RH, Longley D, Marshall J, Cummins R, Sargent DJ, Johnston PG, Harkin DP. J Clin Oncol. 2011 Dec 10; 29(35):4620-6.

Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases. Chao Y, Wu Q, Acquafondata M, Dhir R, Wells A. Cancer Microenviron. 2011 Sep 3.

Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research Network. Nature. 2011 Jun 29;474(7353):609-15.

Identification of Hydroxysteroid (17?) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas. Visus C, Ito D, Dhir R, Szczepanski MJ, Chang YJ, Latimer JJ, Grant SG, Deleo AB. Cancer Immunol Immunother. 2011 Mar 16.

Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate. Tomaszewski JJ, Cummings JL, Parwani AV, Dhir R, Mason JB, Nelson JB, Bacich DJ, O'Keefe DS. Prostate. 2011 Feb 9.

Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. Teng PN, Hood BL, Sun M, Dhir R, Conrads TP. J Proteome Res. 2011 Mar 4; 10(3):1333-42.

Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Chang G, Xu S, Dhir R, Chandran U, O'Keefe DS, Greenberg NM, Gingrich JR. Clin Cancer Res. 2010 Nov 15;16(22):5390-401.

Combined analysis of estrogen receptor {beta}-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Clin Cancer Res. 2011 Jan 1; 17(1):154-64.

A decade of experience in the development and implementation of tissue banking informatics tools for intra and inter-institutional translational research. Amin W, Singh H, Pople AK, Winters S, Dhir R, Parwani AV, Becich MJ. J Pathol Inform. 2010 Aug 10; 1.

Initial experience with a novel pre-sign-out quality assurance tool for review of random surgical pathology diagnoses in a subspecialty-based university practice. Owens SR, Wiehagen LT, Kelly SM, Piccoli AL, Lassige K, Yousem SA, Dhir R, Parwani AV. Am J Surg Pathol. 2010 Sep; 34(9):1319-23.

Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Moschos SJ, Jukic DM, Athanassiou C, Bhargava R, Dacic S, Wang X, Kuan SF, Fayewicz SL, Galambos C, Acquafondata M, Dhir R, Becker D. Hum Pathol. 2010 Sep; 41(9):1286-98. Epub 2010 Jun 18.

Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up. Dvorakova M, Dhir R, Bastacky SI, Cieply KM, Acquafondata MB, Sherer CR, Mercuri TL, Parwani AV. Diagn Pathol. 2010 May 24; 5:32.

The development and testing of a laboratory information system-driven tool for pre-sign-out quality assurance of random surgical pathology reports. Owens SR, Dhir R, Yousem SA, Kelly SM, Piccoli A, Wiehagen L, Lassige K, Parwani AV. Am J Clin Pathol. 2010 Jun; 133(6):836-41.

Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Sakamoto S, McCann RO, Dhir R, Kyprianou N. Cancer Res. 2010 Mar 1; 70(5):1885-95. Epub 2010 Feb 16.

LaFramboise WA, Petrosko P, Kriill-Burger JM, Morris DR, McCoy AR, Scalise D, Malehorn DE, Guthrie RD, Becich MJ, Dhir R. Proteins secreted by embryonic stem cells activate cardiomyocytes through ligand binding pathways. J Proteomics 2010 Jan 4:992-1003.